Drugs / Tetravalent influenza virus lysis vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05107375 | Sep 2021 → Mar 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetravalent influenza virus lysis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107375 ↗ |
| Modality | Vaccine | “Tetravalent influenza virus lysis vaccine” NCT05107375 ↗ |
| Route | Intramuscular | “given intramuscularly in the upper arm deltoid muscle” NCT05107375 ↗ |